Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIq-ai Ltd Regulatory News (IQAI)

Share Price Information for Iq-ai Ltd (IQAI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.60
Bid: 1.50
Ask: 1.70
Change: 0.05 (3.23%)
Spread: 0.20 (13.333%)
Open: 1.55
High: 1.60
Low: 1.55
Prev. Close: 1.55
IQAI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Notice of AGM

3 May 2023 16:14

RNS Number : 3203Y
IQ-AI Limited
03 May 2023
 

 

IQ-AI Ltd

("IQ-AI" or the "Company")

 

Notice of AGM

 

IQ-AI Limited announces that notice of the annual general meeting of the Company, to be held at Third Floor, Forum 4, Grenville Street, St Helier, Jersey, JE2 4UF on 23 May 2023 at 10.30am, has been posted to shareholders.

 

The purpose of the meeting is to consider and, if thought fit, to pass the following resolutions:- 

 

ORDINARY RESOLUTIONS

 

1. To receive, approve and adopt the Company's audited financial statements, together with the reports of the directors and the auditor, for the year ended 31 December 2022.

 

2. To re-elect as a director of the Company, Michael Schmainda (who retires as a director in accordance with the Articles of Association of the Company) and who, being eligible, offers himself for re-election.

 

3. To appoint PKF Littlejohn LLP as auditors of the Company to hold office from the conclusion of the meeting until the conclusion of the next annual general meeting of the Company and to authorise the directors to fix their remuneration.

 

SPECIAL RESOLUTIONS:

 

4. That the Company be generally and unconditionally authorised pursuant to Article 57(2) of the Companies (Jersey) Law 1991 (as amended) to make one or more market purchases of its own shares, such purchases to be of ordinary shares of £0.01 each in the capital of the Company (Ordinary Shares) on the London Stock Exchange, provided that:

 

(a) no purchase of Ordinary Shares may be effected without the affirmative prior sanction by a majority of not less than three fourths of the holders (as to nominal value) of the Company's issued convertible loan notes; and

 

(b) subject to paragraph 4(a) above:

(i) the maximum number of Ordinary Shares hereby authorised to be purchased shall be 27,393,209 Ordinary Shares, being approximately 15% of the issued share capital of the Company;

(ii) the minimum price which may be paid for any such Ordinary Shares shall be

£0.01 per Ordinary Share (exclusive of expenses);

(iii) the maximum price (exclusive of expenses) which may be paid for an Ordinary Share

 

shall not be more than the higher of: (i) an amount equal to 105% of the average of the middle market quotations for an Ordinary Share (as derived from the London Stock Exchange Daily Official List) for the five business days immediately preceding the date on which that Ordinary Share is contracted to be purchased and (ii) the amount stipulated by the Regulatory Technical Standard adopted by the European Commission pursuant to Article 5(6) of the Market Abuse Regulation (EU) No. 596/2014 ;

(iv) unless otherwise varied renewed or revoked the authority hereby conferred shall expire at the conclusion of the next annual general meeting of the Company; and

(v) prior to expiry of the authority hereby conferred the Company may enter into a contract or contracts for the purchase of Ordinary Shares which may be executed in whole or part after such expiry and may purchase Ordinary Shares pursuant to such contract or contracts as if the authority hereby conferred had not so expired.

 

5. The Directors be and they are hereby generally and unconditionally authorised in accordance with Articles 4.14 and 14.6 of the Company's Articles of Association, to allot without rights of pre-emption under Article 4.6 of the Company's Articles of Association, up to 58,382,392 Ordinary Shares as they in their absolute discretion see fit in any number of tranches, such authority unless otherwise varied, renewed or revoked to expire at the conclusion of the next annual general meeting of the Company, except that the Company may, at any time prior to the expiry of such authority, make an offer or enter into an agreement which would or might require Ordinary Shares to be allotted after the expiry of such power and the Directors of the Company may allot Ordinary Shares in pursuance of such an offer or agreement as if such power had not expired.

 

The Directors of the Company accept responsibility for the contents of this announcement

 

-ENDS-

 

For further information, please contact:

IQ-AI Limited

Trevor Brown/Brett Skelly/Vinod Kaushal

Tel: 020 7469 0930

 

Peterhouse Capital Limited (Financial Adviser and Broker)

Lucy Williams/Heena Karani

Tel: 020 7220 9797

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NOABUGDUXBGDGXX
Date   Source Headline
5th Mar 20247:00 amRNSGrant of Options
1st Mar 20248:22 amRNSHolding(s) in Company
1st Mar 20248:20 amRNSHolding(s) in Company
26th Feb 20247:00 amRNSResult of Broker Option and Total Voting Rights
22nd Feb 20247:00 amRNSPlacing and Broker Option
9th Feb 202412:49 pmRNSFDA Application Update
2nd Feb 20248:39 amRNSIB awarded a $100,000 grant
22nd Jan 202410:05 amRNSHolding(s) in Company
15th Jan 20247:01 amRNSDirector Dealings and Conversion of CLNs
15th Jan 20247:00 amRNSHolding(s) in Company
10th Jan 20247:00 amRNSIB Launching an Expanded Access Program for GaM
19th Dec 20232:29 pmRNSImaging Biometrics granted FDA “Fast-Track”
5th Dec 202310:58 amRNSIQ-AI Announces Positive Interim Phase 1 Results
20th Nov 20231:42 pmRNSHolding(s) in Company
9th Nov 202311:38 amRNSDirector Dealing and Conversion of CLNs
8th Nov 202310:59 amRNSApplication for Pediatric Rare Disease Designation
6th Nov 20231:02 pmRNSHolding(s) in Company
18th Oct 20232:29 pmRNSUpdate Regarding Imaging Biometrics LLC
13th Oct 20238:55 amRNSIB Letter to Shareholders
9th Oct 20237:00 amRNSOrphan Drug Status to GaM and Total Voting Rights
3rd Oct 202311:30 amRNSHolding(s) in Company
19th Sep 20232:32 pmRNSIQ-AI shares cease trading on the OTCQB
8th Sep 20237:00 amRNSReduced Gadolinium Approach Validated'
18th Aug 202312:06 pmRNSUpdate on Collaboration Agreement with Mayo Clinic
18th Aug 202311:20 amRNSIB & GE HealthCare Enter into Commercial Agreement
17th Aug 20237:00 amRNSHalf-year Report
19th Jul 20237:00 amRNSImaging Biometrics Installs IB Nimble™ For MCW
13th Jul 20237:00 amRNSOrphan Drug Designation for GaM in Pediatric GBM
27th Jun 20237:00 amRNSStudies Show GaM Inhibits Pediatric Tumor Growth
23rd May 202311:02 amRNSResult of AGM
23rd May 20237:00 amRNSAGM Statement
3rd May 20234:14 pmRNSNotice of AGM
26th Apr 20237:00 amRNSFinal Results
28th Feb 20233:52 pmRNSOrphan Drug Designation Status
13th Jan 20232:05 pmRNSSecond Price Monitoring Extn
13th Jan 20232:00 pmRNSPrice Monitoring Extension
13th Jan 202311:05 amRNSSecond Price Monitoring Extn
13th Jan 202311:00 amRNSPrice Monitoring Extension
10th Jan 20237:00 amRNSLetter to Shareholders
2nd Dec 202211:11 amRNSHolding in Company
25th Oct 202211:00 amRNSPrice Monitoring Extension
30th Sep 20227:00 amRNSLetter to Shareholders
26th Sep 20227:00 amRNSIssue of Warrants to Employees
16th Aug 20224:40 pmRNSSecond Price Monitoring Extn
16th Aug 20224:35 pmRNSPrice Monitoring Extension
16th Aug 20229:28 amRNSHalf-year Report
3rd Aug 20221:01 pmRNSTR1 - Notification of Major Holdings
11th Jul 20227:00 amRNSImaging Biometrics Announces Channel Partnership
31st May 202211:05 amRNSSecond Price Monitoring Extn
31st May 202211:00 amRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.